scholarly article | Q13442814 |
P356 | DOI | 10.1172/JCI1554 |
P8608 | Fatcat ID | release_6oiy5ziwlnea7kbpq3dle7sgcy |
P932 | PMC publication ID | 508567 |
P698 | PubMed publication ID | 9435300 |
P2093 | author name string | L F Thompson | |
R Resta | |||
B N Cronstein | |||
M C Montesinos | |||
L Morabito | |||
G Carlin | |||
L Balter | |||
D M Schreibman | |||
M A Huie | |||
P2860 | cites work | Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g | Q26778365 |
Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients | Q28367735 | ||
5'-adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers | Q33900552 | ||
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. | Q33909650 | ||
Polyglutamation of methotrexate. Is methotrexate a prodrug? | Q34552178 | ||
A human beta-actin expression vector system directs high-level accumulation of antisense transcripts | Q34638492 | ||
Identification of stromal cell products that interact with pre-B cells | Q36237195 | ||
Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. | Q36349017 | ||
A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1 | Q37262115 | ||
Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells | Q37443977 | ||
Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. | Q40822540 | ||
Molecular therapeutics. Methotrexate and its mechanism of action | Q41266413 | ||
Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury | Q41273156 | ||
Glycosyl phosphatidylinositol membrane anchor is not required for T cell activation through CD73. | Q41451353 | ||
Alteration of purine metabolism by AICA-riboside in human B lymphoblasts | Q41717313 | ||
Selective adenosine release from human B but not T lymphoid cell line. | Q41721380 | ||
The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. | Q41817247 | ||
Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release | Q42442065 | ||
Formation and salvage of adenosine by macrovascular endothelial cells. | Q42510656 | ||
Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide | Q42853623 | ||
The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites | Q70988415 | ||
Substrate cycling between 5-amino-4-imidazolecarboxamide riboside and its monophosphate in isolated rat hepatocytes | Q71591729 | ||
The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine | Q72028809 | ||
Attenuation of ecto-5'-nucleotidase activity and adenosine release in activated human polymorphonuclear leukocytes | Q72873670 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | adenine | Q15277 |
sulfasalazine | Q420035 | ||
methotrexate | Q422232 | ||
P304 | page(s) | 295-300 | |
P577 | publication date | 1998-01-01 | |
P1433 | published in | Journal of Clinical Investigation | Q3186904 |
P1476 | title | Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides | |
P478 | volume | 101 |
Q24652486 | A2A receptors in inflammation and injury: lessons learned from transgenic animals |
Q40957424 | ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis |
Q94706466 | Abacavir and increased risk of myocardial infarction |
Q37318889 | Activation of adenosine A(2A) receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFκB nuclear translocation |
Q61454992 | Activation-dependent lymphocyte apoptosis induced by methotrexate |
Q90270036 | Adenosine 2a Receptor Signal Blockade of Murine Autoimmune Arthritis via Inhibition of Pathogenic Germinal Center-Follicular Helper T Cells |
Q35098311 | Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. |
Q35951939 | Adenosine A(2A) receptor ligation inhibits osteoclast formation. |
Q35546429 | Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis |
Q33919462 | Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. |
Q36907484 | Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease |
Q39004042 | Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases |
Q35145661 | Adenosine in the spinal cord and periphery: release and regulation of pain |
Q35747902 | Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. |
Q37165218 | Adenosine receptor agonists for promotion of dermal wound healing |
Q24651475 | Adenosine receptors: therapeutic aspects for inflammatory and immune diseases |
Q44411396 | Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by Ecto-5'-nucleotidase/CD73-dependent mechanism |
Q46074030 | An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis. |
Q24674760 | Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis |
Q28189312 | Antipyretics: mechanisms of action and clinical use in fever suppression |
Q44378768 | Arachidonic acid activates phospholipase D in human neutrophils; essential role of endogenous leukotriene B4 and inhibition by adenosine A2A receptor engagement. |
Q35629308 | Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells |
Q37587400 | Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study |
Q38886498 | Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis |
Q37008144 | Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages |
Q34703746 | Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states |
Q36566752 | CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease |
Q37022867 | Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury |
Q48144426 | Cutting Edge: Adenosine A2a Receptor Signals Inhibit Germinal Center T Follicular Helper Cell Differentiation during the Primary Response to Vaccination |
Q33511367 | Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults |
Q28375106 | Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis |
Q36052531 | Effects of adenosine on adhesion molecule expression and cytokine production in human PBMC depend on the receptor subtype activated |
Q35609523 | Effects of methotrexate upon inflammatory parameters induced by carrageenan in the mouse model of pleurisy |
Q35064975 | Effects of sulfasalazine and tofacitinib on the protein profile of articular chondrocytes |
Q37715322 | Electroacupuncture-induced neuroprotection against focal cerebral ischemia in the rat is mediated by adenosine A1 receptors |
Q24681298 | Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis |
Q36585539 | Extracellular adenosine signaling in molecular medicine |
Q33878542 | Extracellular adenosine-mediated modulation of regulatory T cells |
Q90633451 | Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications |
Q34293811 | Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation |
Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
Q44590749 | HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis |
Q46339684 | IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. |
Q39067604 | Immune resolution mechanisms in inflammatory arthritis |
Q33908046 | Immunosuppressive drugs: the first 50 years and a glance forward |
Q37383893 | Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells |
Q36578046 | Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir |
Q43513980 | Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells |
Q33731467 | It is time to ask what adenosine can do for cardioprotection |
Q33810422 | Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis. |
Q37193206 | Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line |
Q77211932 | Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx |
Q38991972 | Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. |
Q33957205 | Mechanisms of action of methotrexate. |
Q36085841 | Mechanisms of action of mycophenolate mofetil |
Q38379218 | MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS. |
Q36063391 | Methotrexate Increases Skeletal Muscle GLUT4 Expression and Improves Metabolic Control in Experimental Diabetes |
Q33723415 | Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis |
Q91607122 | Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study |
Q33869850 | Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? |
Q47725430 | Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast |
Q35636960 | Methotrexate modulates the kinetics of adenosine in humans in vivo |
Q73526256 | Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis |
Q36863538 | Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment. |
Q43144564 | Methotrexate--how does it really work? |
Q24534771 | Molecular action of methotrexate in inflammatory diseases |
Q36404222 | Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation |
Q38203832 | Pediatric ulcerative colitis: a practical guide to management |
Q35555878 | Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study |
Q38097969 | Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis |
Q35049306 | Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases |
Q37006166 | Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases |
Q36478279 | Physiological roles for ecto-5'-nucleotidase (CD73). |
Q27000719 | Potential for developing purinergic drugs for gastrointestinal diseases |
Q73195234 | Potentiation of formalin-evoked adenosine release by an adenosine kinase inhibitor and an adenosine deaminase inhibitor in the rat hind paw: a microdialysis study |
Q39737673 | Prostaglandin E₂regulation of cystic fibrosis transmembrane conductance regulator activity and airway surface liquid volume requires gap junctional communication |
Q92404916 | Purinergic Signaling in Pulmonary Inflammation |
Q34034751 | Purinergic signaling during inflammation |
Q35637808 | Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis |
Q49069370 | Rationale and design of the TETHYS trial: the effects of methotrexate therapy on myocardial infarction with ST-segment elevation |
Q35990760 | Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). |
Q37442054 | Regulation of bone and cartilage by adenosine signaling. |
Q38265002 | Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease |
Q37208648 | Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. |
Q44114291 | Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis |
Q43140401 | Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. |
Q46473226 | Stimulation of ecto-5'-nucleotidase in human umbilical vein endothelial cells by lipopolysaccharide |
Q34896844 | Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. |
Q33557318 | TRANSLATION OF BRAIN ACTIVITY INTO SLEEP. |
Q41005023 | Tenidap enhances P2Z/P2X7 receptor signalling in macrophages |
Q53395308 | The Outsiders: Emerging Roles of Ectonucleotidases in Inflammation |
Q33768462 | The P2Z/P2X7 receptor of microglial cells: a novel immunomodulatory receptor. |
Q92999338 | The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases |
Q52587889 | The Role of Adenosine Receptor Activation in Attenuating Cartilaginous Inflammation. |
Q46443898 | The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study |
Q36059527 | Treatment and management of pseudogout: insights for the clinician |
Search more.